

Express Mail No. EL 998649300 US

R² is 3-aminophenyl, B is 3-hydroxypropyl, A is single bond, Y⁰ is 4-amidinobenzyl, R¹ is aminomethyl, and X⁰ is hydrido;

R² is 3-aminophenyl, B is 2-methylpropyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, R¹ is aminomethyl, and X⁰ is hydrido;

R² is 3-aminophenyl, B is butyl, A is single bond, Y⁰ is 4-amidinobenzyl, R¹ is aminomethyl, and X⁰ is hydrido;

R² is 3-aminophenyl, B is 3-methoxy-2-propyl, A is single bond, Y⁰ is 4-amidinobenzyl, R¹ is aminomethyl, and X⁰ is hydrido;

R² is 3-aminophenyl, B is 3-methoxy-2-propyl, A is single bond, Y⁰ is 4-amidinobenzyl, R¹ is aminomethyl, and X⁰ is hydrido;

R² is 3-aminophenyl, B is 2-methoxy-2-ethyl, A is single bond, Y⁰ is 4-amidinobenzyl, R¹ is aminomethyl, and X⁰ is hydrido;

R² is 3-aminophenyl, B is 2-propyl, A is single bond, Y⁰ is 5-amidino-2-thienylmethyl, R¹ is aminomethyl, and X⁰ is hydrido;

R² is 3-aminophenyl, B is 2-propyl, A is single bond, Y⁰ is 4-amidino-3-fluorobenzyl, R¹ is aminomethyl, and X⁰ is hydrido;

R² is 3-carboxyphenyl, B is 2-propyl, A is single bond, Y⁰ is 4-amidinobenzyl, R¹ is aminomethyl, and X⁰ is hydrido; or

R² is 3-aminophenyl, B is 2-propyl, A is single bond, Y⁰ is 4-amidino-3-fluorobenzyl, R¹ is aminomethyl, and X⁰ is hydrido.

Claims 25-45 (canceled)

Claim 46 (currently amended): A composition for ^{treating} ~~inhibiting~~ thrombotic conditions in blood comprising a compound of ~~any one of claims 4 or 40~~ claim 24 and a pharmaceutically acceptable carrier.

Claim 47 (currently amended): A composition for ^{treating} ~~inhibiting~~ thrombotic conditions in blood comprising a compound of any one of claims 17 through 23, ~~or claims 33 through 39~~, and a pharmaceutically acceptable carrier.

Examiner's
Amendment
6-17-04

Express Mail No. EL 998649300 US

*Examiner's
Amendment
6-17-04*

Claim 48 (currently amended): A method for ^{treating} ~~inhibiting~~ thrombotic conditions in blood comprising adding to blood a therapeutically effective amount of a composition of ~~any one of claims~~ claim 46 or 47.

Claim 49 (currently amended): A method for inhibiting formation of blood platelet aggregates in blood comprising adding to blood a therapeutically effective amount of a composition of ~~any one of claims~~ claim 46 or 47.

Claim 50 (currently amended): A method for inhibiting thrombus formation in blood comprising adding to blood a therapeutically effective amount of a composition of ~~any one of claims~~ claim 46 or 47.

Claim 51 (currently amended): A method for treating ~~or preventing~~ venous thromboembolism and pulmonary embolism in a mammal comprising administering to the mammal a therapeutically effective amount of a composition of ~~any one of claims~~ claim 46 or 47.

*Examiner's
Amendment
6-17-04*

Claim 52 (currently amended): A method for treating ~~or preventing~~ deep vein thrombosis in a mammal comprising administering to the mammal a therapeutically effective amount of a composition of ~~any one of claims~~ claim 46 or 47.

Claim 53 (currently amended): A method for treating ~~or preventing~~ cardiogenic thromboembolism in a mammal comprising administering to the mammal a therapeutically effective amount of a composition of ~~any one of claims~~ claim 46 or 47.

Claim 54 (currently amended): A method for treating ~~or preventing~~ thromboembolic stroke in humans and other mammals comprising administering to the mammal a therapeutically effective amount of a composition of ~~any one of claims~~ claim 46 or 47.

Express Mail No. EL 998649300 US

*Examiner's
Amendment
6-17-04*

Claim 55 (currently amended): A method for treating ~~or preventing~~ thrombosis associated with cancer and cancer chemotherapy in humans and other mammals comprising administering to the mammal a therapeutically effective amount of a composition of ~~any one of claims~~ claim 46 or 47.

Claim 56 (currently amended): A method for treating ~~or preventing~~ Unstable angina in humans and other mammals comprising administering to the mammal a therapeutically effective amount of a composition of ~~any one of claims~~ claim 46 or 47.

Claim 57 (currently amended): A method for inhibiting thrombus formation in blood comprising adding to blood a therapeutically effective amount of a compound of any one of claims 17-24 ~~or 33-40~~ with a therapeutically effective amount of fibrinogen receptor antagonist.